듀센형 근이영양증 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Duchenne Muscular Dystrophy Treatment Market is expected to increase at a CAGR of 8.9% for the forecast period, growing from USD 1.74 billion in 2026 to USD 3.75 billion by 2035.

Duchenne Muscular Dystrophy (DMD) is a severe and progressive genetic neuromuscular disorder caused by mutations in the dystrophin gene, resulting in muscle degeneration, loss of ambulation, respiratory complications, cardiac dysfunction, and reduced life expectancy. Historically, treatment focused on corticosteroids, physical therapy, orthopedic support, and symptomatic management. However, the therapeutic landscape is undergoing a fundamental transformation as innovative genetic and molecular therapies move from clinical development into commercial practice. The emergence of exon-skipping therapies, gene replacement therapies, antisense oligonucleotides, and other mutation-specific treatments is redefining standards of care and creating substantial opportunities for market expansion.

The growing understanding of DMD genetics, coupled with advances in molecular diagnostics and precision medicine, is improving patient identification and treatment eligibility. Healthcare providers, pharmaceutical companies, patient advocacy organizations, and regulatory agencies are increasingly collaborating to accelerate therapeutic innovation and improve access to advanced treatments. As a result, the DMD treatment market is transitioning from supportive care toward disease-modifying and potentially transformative therapies.

Market Drivers

Rapid Advancement of Gene Therapy Technologies

One of the most significant growth drivers is the advancement of gene therapy platforms designed to address the underlying genetic cause of DMD. Gene therapies seek to restore dystrophin production and potentially provide long-term therapeutic benefits through a single treatment intervention.

Growing clinical success, regulatory approvals, and investment in gene therapy manufacturing capabilities are accelerating market growth and expanding future treatment opportunities. The increasing acceptance of genetic medicines is encouraging pharmaceutical companies to strengthen their DMD pipelines and pursue innovative therapeutic approaches.

Rising Adoption of Mutation-Specific Therapies

The market is increasingly shifting toward precision medicine approaches. Exon-skipping therapies and mutation-targeted treatments provide personalized treatment options for specific patient subgroups based on their genetic mutation profile.

As comprehensive genetic testing becomes standard practice in DMD diagnosis, a larger proportion of patients can be matched with targeted therapies, supporting treatment adoption and market expansion.

Favorable Orphan Drug Incentives

Regulatory frameworks supporting orphan drug development continue to stimulate investment in DMD therapeutics. Incentives such as market exclusivity, tax credits, expedited review pathways, and regulatory support improve the commercial attractiveness of rare disease drug development.

These incentives have encouraged pharmaceutical and biotechnology companies to invest aggressively in DMD research and commercialization activities.

Increasing Awareness and Early Diagnosis

Growing awareness among healthcare professionals, patient advocacy organizations, and caregivers is contributing to earlier diagnosis and improved disease management. Enhanced access to genetic testing and newborn screening initiatives in certain regions are further strengthening patient identification efforts.

Earlier diagnosis allows patients to access treatment sooner and supports participation in clinical trials evaluating emerging therapies.

Market Restraints

High Cost of Advanced Therapies

Gene therapies and molecular treatments involve complex manufacturing processes, extensive clinical development programs, and specialized administration requirements. These factors contribute to high treatment costs and create affordability challenges for healthcare systems and payers.

Pricing concerns may limit patient access and lead to reimbursement negotiations that delay market adoption in some regions.

Limited Patient Population

DMD is a rare disease affecting a relatively small patient population. The limited number of eligible patients can increase development costs, complicate clinical trial recruitment, and restrict commercial scalability compared with larger therapeutic markets.

The rarity of the disease also contributes to challenges in establishing specialized treatment infrastructure in certain countries.

Regulatory and Clinical Uncertainty

Novel genetic therapies require extensive regulatory scrutiny regarding safety, durability, and long-term efficacy. Regulatory requirements for advanced therapies remain rigorous and may prolong development timelines or create commercialization risks.

Long-term monitoring requirements and evolving regulatory expectations continue to present challenges for therapy developers.

Technology and Segment Insights

The global Duchenne Muscular Dystrophy treatment market can be segmented by test type, treatment type, therapy approach, route of administration, distribution channel, end user, and geography.

By test type, the market includes blood tests, molecular genetic testing, electromyography, muscle biopsy, and other diagnostic approaches. Molecular genetic testing represents one of the most important segments because it enables confirmation of specific mutations and supports personalized treatment selection.

By treatment type, the market includes physical therapy, orthopedic devices, steroids, gene therapies, exon-skipping therapies, mutation suppression therapies, and other emerging treatment modalities. While corticosteroids continue to play an important role in disease management, advanced molecular therapies are expected to capture an increasing share of market revenue during the forecast period.

By therapy approach, the market includes corticosteroids, exon-skipping therapies, gene therapies, antisense oligonucleotides, stem cell therapies, mutation suppression therapies, and dystrophin-targeted treatments. Exon-skipping therapies currently represent a significant segment, while gene therapies are expected to be among the fastest-growing categories due to their transformative potential.

By route of administration, the market includes oral, intravenous, subcutaneous, and other administration methods. Oral therapies remain important for long-term disease management, while intravenous administration is increasingly associated with advanced biological and genetic therapies.

By distribution channel, the market includes hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies. Hospital and specialty pharmacies account for a substantial share due to the specialized nature of treatment administration and patient monitoring requirements.

By end user, the market includes hospitals, specialty clinics, academic medical centers, rehabilitation facilities, and home healthcare providers. Hospitals remain the dominant end-user segment due to their ability to deliver multidisciplinary care and advanced therapeutic interventions.

Technological innovation continues to reshape the market through gene editing, next-generation sequencing, artificial intelligence-driven drug discovery, digital health monitoring, biomarker development, and precision medicine platforms. These advancements improve treatment selection, clinical trial efficiency, patient monitoring, and long-term disease management.

Geographically, North America leads the market due to strong rare disease research capabilities, favorable reimbursement environments, extensive clinical trial activity, and early adoption of innovative therapies. Europe maintains a significant position supported by orphan drug policies and advanced healthcare infrastructure. Asia-Pacific is expected to experience rapid growth owing to expanding healthcare investment, increasing genetic testing capabilities, and improving awareness of rare diseases. Latin America and the Middle East & Africa are gradually strengthening access to specialized neuromuscular care and advanced therapies.

Competitive and Strategic Outlook

The competitive landscape is characterized by intense innovation and significant investment in advanced therapeutic development. Pharmaceutical and biotechnology companies are competing to develop therapies that restore dystrophin expression, slow disease progression, and improve functional outcomes.

Market participants are actively pursuing strategic partnerships, licensing agreements, acquisitions, and collaborative research initiatives to strengthen technological capabilities and accelerate commercialization. Companies are also investing in manufacturing infrastructure and global market access strategies to support future product launches.

Leading organizations are advancing pipelines across gene therapy, exon-skipping, antisense oligonucleotide, and mutation suppression platforms. Competitive differentiation is increasingly based on efficacy, durability of response, safety profile, treatment eligibility, and long-term patient outcomes. As additional therapies enter the market, competition is expected to intensify across both established and emerging treatment categories.

Conclusion

The global Duchenne Muscular Dystrophy treatment market is poised for strong growth through 2031, driven by advances in gene therapy, precision medicine, mutation-specific treatments, and rare disease research. The market is transitioning from conventional supportive care toward innovative disease-modifying interventions capable of addressing the underlying genetic causes of the disease. While challenges related to treatment costs, regulatory complexity, and limited patient populations remain, ongoing therapeutic innovation and favorable orphan drug incentives are expected to create substantial growth opportunities. Continued collaboration among industry stakeholders, healthcare providers, researchers, and patient advocacy organizations will remain essential to advancing treatment outcomes and expanding patient access worldwide.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings and Strategic Insights
• 1.3 Duchenne Muscular Dystrophy (DMD) Market Snapshot
• 1.4 Key Commercialized Therapies Overview
• 1.5 Pipeline Development Highlights
• 1.6 Regulatory and Reimbursement Overview
• 1.7 Future Growth Opportunities
• 1.8 Analyst Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Duchenne Muscular Dystrophy
  • 2.1.1 Disease Definition and Clinical Characteristics
  • 2.1.2 Genetic Basis and Dystrophin Deficiency
  • 2.1.3 Disease Progression and Natural History
  • 2.1.4 Disease Burden and Unmet Needs
• 2.2 Epidemiology Overview
  • 2.2.1 Global Prevalence and Incidence
  • 2.2.2 Diagnosed Patient Population
  • 2.2.3 Age-Specific Distribution
  • 2.2.4 Gender-Specific Distribution
  • 2.2.5 Mortality and Survival Trends
• 2.3 DMD Subtype Analysis
  • 2.3.1 Exon 51 Amenable Population
  • 2.3.2 Exon 53 Amenable Population
  • 2.3.3 Exon 45 Amenable Population
  • 2.3.4 Non-Amenable Mutation Population
  • 2.3.5 Ambulatory vs Non-Ambulatory Patients
• 2.4 Disease Burden Assessment
  • 2.4.1 Clinical Burden
  • 2.4.2 Economic Burden
  • 2.4.3 Caregiver Burden
  • 2.4.4 Quality of Life Impact

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Increasing Genetic Testing and Early Diagnosis
  • 3.2.2 Advancements in Gene Therapy Development
  • 3.2.3 Growing Rare Disease Funding and Support Programs
  • 3.2.4 Expanding Regulatory Incentives for Orphan Drugs
• 3.3 Market Restraints
  • 3.3.1 High Cost of Advanced Therapies
  • 3.3.2 Limited Patient Eligibility for Mutation-Specific Therapies
  • 3.3.3 Manufacturing and Supply Chain Challenges
  • 3.3.4 Long-Term Safety and Durability Concerns
• 3.4 Market Opportunities
  • 3.4.1 Next-Generation Gene Therapies
  • 3.4.2 Combination Treatment Approaches
  • 3.4.3 Expansion into Non-Ambulatory Patient Segments
  • 3.4.4 Emerging Markets Penetration
• 3.5 Market Challenges
  • 3.5.1 Reimbursement Constraints
  • 3.5.2 Clinical Trial Recruitment Difficulties
  • 3.5.3 Regulatory Complexity Across Regions
• 3.6 Porter's Five Forces Analysis
• 3.7 PESTLE Analysis
• 3.8 Value Chain Analysis
• 3.9 Stakeholder Ecosystem Analysis

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 Product Commercialization Strategies
• 4.3 Pricing Analysis of Approved DMD Therapies
• 4.4 Reimbursement Framework Assessment
  • 4.4.1 Public Reimbursement Systems
  • 4.4.2 Private Insurance Coverage
  • 4.4.3 Managed Access Programs
• 4.5 Market Access Challenges
• 4.6 Orphan Drug Incentives and Impact
• 4.7 Patient Assistance Programs
• 4.8 Health Technology Assessment (HTA) Considerations

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline Distribution by Development Phase
  • 5.2.1 Discovery and Preclinical Stage
  • 5.2.2 Phase I
  • 5.2.3 Phase II
  • 5.2.4 Phase III
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Gene Replacement Therapies
  • 5.3.2 Exon Skipping Therapies
  • 5.3.3 Gene Editing Approaches
  • 5.3.4 Cell-Based Therapies
  • 5.3.5 Small Molecule Therapies
  • 5.3.6 RNA-Based Therapeutics
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Micro-Dystrophin Gene Transfer
  • 5.4.2 Exon Skipping Mechanisms
  • 5.4.3 Utrophin Modulation
  • 5.4.4 Anti-Fibrotic Mechanisms
  • 5.4.5 Muscle Regeneration Approaches
  • 5.4.6 Anti-Inflammatory Approaches
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Clinical Studies
  • 5.5.2 Recruitment Trends
  • 5.5.3 Trial Endpoint Analysis
  • 5.5.4 Key Development Milestones
• 5.6 Emerging Technologies and Innovation Trends
• 5.7 Academic and Industry Collaborations
• 5.8 Licensing, Partnerships, and M&A Activity

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Standard of Care Overview
  • 6.2.1 Corticosteroid Therapy
  • 6.2.2 Cardiac Management
  • 6.2.3 Respiratory Management
  • 6.2.4 Orthopedic Interventions
  • 6.2.5 Rehabilitation and Physiotherapy
• 6.3 Approved Disease-Modifying Therapies
  • 6.3.1 Exondys 51 (eteplirsen)
  • 6.3.2 Vyondys 53 (golodirsen)
  • 6.3.3 Viltepso (viltolarsen)
  • 6.3.4 Amondys 45 (casimersen)
  • 6.3.5 Elevidys (delandistrogene moxeparvovec-rokl)
  • 6.3.6 Agamree (vamorolone)
• 6.4 Treatment Algorithm Analysis
• 6.5 Comparative Assessment of Available Therapies
• 6.6 Emerging Treatment Approaches

7. Global Duchenne Muscular Dystrophy Treatment Landscape Report Size & Forecast

• 7.1 Market Size Overview (Historical and Forecast)
• 7.2 Forecast Assumptions and Methodology
• 7.3 Market Revenue Forecast by Therapy Type
• 7.4 Market Revenue Forecast by Route of Administration
• 7.5 Market Revenue Forecast by Distribution Channel
• 7.6 Market Revenue Forecast by End User
• 7.7 Market Revenue Forecast by Region
• 7.8 Scenario Analysis
  • 7.8.1 Base Case Scenario
  • 7.8.2 Optimistic Scenario
  • 7.8.3 Conservative Scenario

8. Global Duchenne Muscular Dystrophy Treatment Landscape Report Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Corticosteroids
  • 8.1.2 Exon Skipping Therapies
  • 8.1.3 Gene Therapies
  • 8.1.4 Emerging Molecular Therapies
• 8.2 By Drug Class
  • 8.2.1 Antisense Oligonucleotides
  • 8.2.2 Viral Vector-Based Gene Therapies
  • 8.2.3 Corticosteroid Derivatives
  • 8.2.4 Small Molecule Therapeutics
• 8.3 By Route of Administration
  • 8.3.1 Intravenous
  • 8.3.2 Oral
  • 8.3.3 Intramuscular
  • 8.3.4 Other Routes
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Specialty Neuromuscular Centers
  • 8.4.3 Ambulatory Care Centers
  • 8.4.4 Home Care Settings
• 8.5 By Distribution Channel
  • 8.5.1 Hospital Pharmacies
  • 8.5.2 Specialty & Retail Pharmacies
  • 8.5.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Growth Trends
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Growth Trends
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth Trends
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Growth Trends
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth Trends
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Product Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 Orphan Drug Regulations
• 11.3 United States (FDA)
  • 11.3.1 Approval Pathways
  • 11.3.2 Accelerated Approval Programs
  • 11.3.3 Rare Pediatric Disease Designation
• 11.4 Europe (EMA)
  • 11.4.1 Orphan Medicinal Product Framework
  • 11.4.2 Centralized Approval Procedures
• 11.5 Japan (PMDA)
  • 11.5.1 Orphan Drug Approval Framework
  • 11.5.2 Regenerative Medicine Regulations
• 11.6 India (CDSCO)
  • 11.6.1 New Drug Approval Requirements
  • 11.6.2 Rare Disease Policy Framework
• 11.7 China (NMPA)
  • 11.7.1 Rare Disease Regulatory Pathways
  • 11.7.2 Accelerated Review Programs
• 11.8 Regulatory Comparison Across Major Markets
• 11.9 Market Access and Pricing Policies
• 11.10 Future Regulatory Developments

12. Competitive Landscape

• 12.1 Market Structure Analysis
• 12.2 Market Share Assessment
• 12.3 Competitive Benchmarking
• 12.4 Product Portfolio Comparison
• 12.5 Pipeline Competitiveness Assessment
• 12.6 Strategic Initiatives Analysis
  • 12.6.1 Collaborations and Partnerships
  • 12.6.2 Licensing Agreements
  • 12.6.3 Acquisitions and Investments
• 12.7 Clinical Development Competitiveness
• 12.8 SWOT Analysis of Leading Participants
• 12.9 Future Competitive Outlook

13. Company Profiles

• 13.1 Sarepta Therapeutics
  • 13.1.1 Company Overview
  • 13.1.2 Approved DMD Products (Exondys 51, Vyondys 53, Amondys 45, Elevidys)
  • 13.1.3 Key Indications
  • 13.1.4 Clinical Pipeline
  • 13.1.5 Strategic Outlook
• 13.2 NS Pharma
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product (Viltepso)
  • 13.2.3 Key Indications
  • 13.2.4 Clinical Pipeline
  • 13.2.5 Strategic Outlook
• 13.3 Santhera Pharmaceuticals
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product (Agamree)
  • 13.3.3 Key Indications
  • 13.3.4 Clinical Pipeline
  • 13.3.5 Strategic Outlook
• 13.4 Pfizer Inc.
  • 13.4.1 Company Overview
  • 13.4.2 Neuromuscular Disease Portfolio
  • 13.4.3 Key Indications
  • 13.4.4 Verified Clinical Pipeline
  • 13.4.5 Strategic Outlook
• 13.5 Wave Life Sciences
  • 13.5.1 Company Overview
  • 13.5.2 Neurodegenerative Disease Portfolio
  • 13.5.3 Key Indications
  • 13.5.4 Verified Clinical Pipeline
  • 13.5.5 Strategic Outlook
• 13.6 Capricor Therapeutics
  • 13.6.1 Company Overview
  • 13.6.2 Neurological Disease Portfolio
  • 13.6.3 Key Indications
  • 13.6.4 Verified Clinical Pipeline
  • 13.6.5 Strategic Outlook
• 13.7 Roche Holding AG
  • 13.7.1 Company Overview
  • 13.7.2 Rare and Neurological Disease Portfolio
  • 13.7.3 Key Indications
  • 13.7.4 Verified Clinical Pipeline
  • 13.7.5 Strategic Outlook
• 13.8 Ultragenyx Pharmaceutical
  • 13.8.1 Company Overview
  • 13.8.2 Neurology Portfolio
  • 13.8.3 Key Indications
  • 13.8.4 Verified Clinical Pipeline
  • 13.8.5 Strategic Outlook
• 13.9 Satellos Bioscience
  • 13.9.1 Company Overview
  • 13.9.2 Neurodegenerative Disease Portfolio
  • 13.9.3 Key Indications
  • 13.9.4 Verified Clinical Pipeline
  • 13.9.5 Strategic Outlook
• 13.10 REGENXBIO
  • 13.10.1 Company Overview
  • 13.10.2 Neurological Disease Portfolio
  • 13.10.3 Key Indications
  • 13.10.4 Verified Clinical Pipeline
  • 13.10.5 Strategic Outlook

14. Future Outlook

• 14.1 Future Market Projections
• 14.2 Emerging Therapeutic Trends
• 14.3 Next-Generation Gene Therapy Outlook
• 14.4 Precision Medicine Evolution in DMD
• 14.5 Commercial Opportunity Assessment
• 14.6 Investment and Funding Trends
• 14.7 Key Strategic Recommendations
• 14.8 Long-Term Market Outlook to Forecast Period

15. Methodology

• 15.1 Research Methodology Overview
• 15.2 Secondary Research Sources
• 15.3 Primary Research Approach
• 15.4 Epidemiology Modeling Framework
• 15.5 Market Forecasting Methodology
• 15.6 Pipeline Assessment Methodology
• 15.7 Competitive Intelligence Framework
• 15.8 Data Validation and Triangulation
• 15.9 Assumptions and Limitations
• 15.10 Abbreviations and Definitions